Evidence map›Paper›PMID 39457004›Full record

ArticleInternational journal of molecular sciences2024

TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma.

Sanjive Qazi, Vuong Trieu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. SpatialESD: Spatial Ensemble Domain Detection in Spatial Transcriptomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Bioinformatic Approach to Identify PotentialInternational journal of molecular sciences · 2025
    Article
  4. Bioinformatic Approach to Identify Positive PrognosticInternational journal of molecular sciences · 2025
    Article
  5. Article
  6. Article
  7. International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sanjive QaziOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.
Vuong TrieuOncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA.ORCID 0000-0002-6675-0811

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of pancreatic ductal adenocarcinoma (PDAC) is an unmet challenge, with the median overall survival rate remaining less than a year, even with the use of FOLFIRINOX-based therapies. This study analyzed archived macrophage-associated mRNA expression using datasets deposited in the UCSC Xena web platform to compare normal pancreatic tissue and PDAC tumor samples. The

Indexed as

Carcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticInterferon-Stimulated Gene Factor 3, gamma SubunitPancreatic NeoplasmsRNA, MessengerTransforming Growth Factor beta2AgedBiomarkers, TumorFemaleGalectinsHumansMaleMembrane ProteinsMiddle AgedPrognosisReceptor, Interferon alpha-betaBiomarkers, TumorGalectinsInterferon-Stimulated Gene Factor 3, gamma SubunitLGALS9 protein, humanMembrane ProteinsReceptor, Interferon alpha-betaRNA, MessengerTGFB2 protein, humanTransforming Growth Factor beta2biomarkersimmune checkpointinterferon-alpha receptormRNApancreatic cancerPDACRNAseqTAMsTGFB2TGF betatumor microenvironment

Identifiers

PMID39457004
PMCPMC11508538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.